Seattle Genetics, Inc. (NASDAQ:SGEN) insider Vaughn B. Himes sold 10,000 shares of the stock in a transaction dated Friday, September 8th. The shares were sold at an average price of $53.22, for a total value of $532,200.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Vaughn B. Himes also recently made the following trade(s):
- On Monday, August 28th, Vaughn B. Himes sold 6,377 shares of Seattle Genetics stock. The shares were sold at an average price of $47.89, for a total value of $305,394.53.
Shares of Seattle Genetics, Inc. (NASDAQ SGEN) opened at 53.15 on Wednesday. Seattle Genetics, Inc. has a 12-month low of $45.31 and a 12-month high of $75.36. The firm’s market capitalization is $7.60 billion. The company’s 50-day moving average price is $49.74 and its 200 day moving average price is $59.41.
Seattle Genetics (NASDAQ:SGEN) last posted its quarterly earnings data on Thursday, July 27th. The biotechnology company reported ($0.39) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.42) by $0.03. The firm had revenue of $108.20 million during the quarter, compared to the consensus estimate of $105.92 million. Seattle Genetics had a negative return on equity of 32.87% and a negative net margin of 47.38%. The firm’s revenue was up 13.4% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.23) EPS. On average, equities research analysts forecast that Seattle Genetics, Inc. will post ($1.69) EPS for the current fiscal year.
A number of institutional investors and hedge funds have recently bought and sold shares of SGEN. Bank of Montreal Can raised its stake in Seattle Genetics by 280.2% during the 1st quarter. Bank of Montreal Can now owns 7,235 shares of the biotechnology company’s stock valued at $454,000 after acquiring an additional 5,332 shares during the last quarter. Capstone Asset Management Co. increased its position in Seattle Genetics by 7.4% during the 1st quarter. Capstone Asset Management Co. now owns 5,055 shares of the biotechnology company’s stock worth $318,000 after purchasing an additional 350 shares during the period. Nationwide Fund Advisors acquired a new position in Seattle Genetics during the 1st quarter worth approximately $1,402,000. DUPONT CAPITAL MANAGEMENT Corp acquired a new position in Seattle Genetics during the 1st quarter worth approximately $494,000. Finally, Sumitomo Mitsui Asset Management Company LTD increased its position in Seattle Genetics by 15.5% during the 1st quarter. Sumitomo Mitsui Asset Management Company LTD now owns 7,982 shares of the biotechnology company’s stock worth $501,000 after purchasing an additional 1,070 shares during the period. 97.70% of the stock is owned by hedge funds and other institutional investors.
A number of research analysts have recently weighed in on the company. Barclays PLC reissued a “hold” rating on shares of Seattle Genetics in a report on Friday, June 23rd. BidaskClub lowered Seattle Genetics from a “hold” rating to a “sell” rating in a report on Wednesday, June 28th. Jefferies Group LLC reissued a “buy” rating and issued a $53.00 price objective on shares of Seattle Genetics in a report on Thursday, July 27th. ValuEngine raised Seattle Genetics from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Finally, Cowen and Company reissued a “hold” rating and issued a $54.00 price objective on shares of Seattle Genetics in a report on Friday, July 28th. Four equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $62.29.
Seattle Genetics Company Profile
Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC).
Receive News & Ratings for Seattle Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.